volociximab   Click here for help

GtoPdb Ligand ID: 10236

Synonyms: M200
Compound class: Antibody
Comment: Volociximab is a chimeric human IgG4 anti-integrin α5 subunit monoclonal antibody [5]. It blocks the interaction between α5β1 and fibronectin and inhibits the complex's functional activity [4], and was originally developed for anti-angiogenic, anti-tumour potential [1-2]. Volociximab does not cross-react with murine α5β1 so is unsuitable for use in standard xenograft models [2]. A rat anti-mouse function-blocking α5β1 designed for murine experiments has been reported (339.1, Kd 0.59 nM), and like volociximab it inhibits angiogenesis and slows tumour growth in vivo[3].
Click here for help
1. Almokadem S, Belani CP. (2012)
Volociximab in cancer.
Expert Opin Biol Ther, 12 (2): 251-7. [PMID:22192080]
2. Bhaskar V, Fox M, Breinberg D, Wong MH, Wales PE, Rhodes S, DuBridge RB, Ramakrishnan V. (2008)
Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits.
Invest New Drugs, 26 (1): 7-12. [PMID:17786386]
3. Bhaskar V, Zhang D, Fox M, Seto P, Wong MH, Wales PE, Powers D, Chao DT, Dubridge RB, Ramakrishnan V. (2007)
A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo.
J Transl Med, 5: 61. [PMID:18042290]
4. Ng CM, Bai S, Takimoto CH, Tang MT, Tolcher AW. (2010)
Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients.
Cancer Chemother Pharmacol, 65 (2): 207-17. [PMID:19468731]
5. Ramakrishnan V, Bhaskar V, Law DA, Wong MH, DuBridge RB, Breinberg D, O'Hara C, Powers DB, Liu G, Grove J et al.. (2006)
Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent.
J Exp Ther Oncol, 5 (4): 273-86. [PMID:17024968]